INmune Bio, Inc. Announces Design of Upcoming Phase 2 Alzheimer’s Disease Clinical Trial and New Phase 1b AD Biomarker Data

Phase 2 study of XProTM will be a six-month, blinded, randomized, placebo-controlled trial in 168 patients with mild Alzheimer’s disease and biomarkers of inflammation. Additional analysis from the Phase 1b study of XProTM demonstrates improvements in white matter analytics within three months in all patients treated with 1.0 mg/kg which supports the dose and duration of the Phase II trial. Recent $40 million financing provides runway to Phase 2 Alzheimer’s data.

Thank you for visiting Tailwinds Research. We are pleased to offer free research on select small and micro cap companies. It is free to join and we hope you’ll take the time to do so.

To create an account please click on this link.

If you already have an account, please log in here.



Please enter your comment!
Please enter your name here